Patient portrayal of a woman enjoying time with family Patient portrayal of a woman enjoying time with family

How VANFLYTA
treats newly diagnosed
FLT3-ITD+ AML

In a study, VANFLYTA helped people live longer than those who were treated with chemotherapy alone

VANFLYTA was studied in a clinical trial of 539 people who were newly diagnosed with FLT3-ITD+ AML. To learn how effective VANFLYTA is, some people in the trial received VANFLYTA and chemotherapy while other people received placebo and chemotherapy alone. In this trial, 268 people were treated with VANFLYTA and chemotherapy, and 271 people were treated with placebo and chemotherapy alone.

The results of the study showed that VANFLYTA increased overall survival. That is, people taking VANFLYTA and chemotherapy lived longer than people who were treated with placebo and chemotherapy alone.

VANFLYTA patient portrayal
People taking
VANFLYTA lived longer
Not an actual patient.
VANFLYTA patient portrayal VANFLYTA patient portrayal
People taking VANFLYTA lived longer
Not an actual patient.

People taking VANFLYTA and chemotherapy were
22% LESS LIKELY to die as a result of their cancer compared to placebo and chemotherapy alone.

At the time of primary analysis,
135 out of 268 people treated with VANFLYTA plus chemotherapy were alive;
113 out of 271 people treated with placebo plus chemotherapy were alive.

Patient portrayal of a woman sitting down with family
VANFLYTA WAS STUDIED FOR
COMPLETE REMISSION AND
HOW LONG PEOPLE STAYED IN
REMISSION
Not an actual patient.
Patient portrayal of a woman sitting down with family Patient portrayal of a woman sitting down with family
VANFLYTA WAS STUDIED FOR COMPLETE REMISSION AND HOW LONG PEOPLE STAYED IN REMISSION
Not an actual patient.

55% of people taking VANFLYTA with chemotherapy (147 out of 268) and 55% of people taking placebo plus chemotherapy (150 out of 271) achieved complete remission of the cancer.

  • VANFLYTA was also studied for composite complete remission, which is defined as complete remission (which means no evidence of cancer) or complete remission with incomplete hematological recovery (which means no evidence of cancer and blood counts might have not fully recovered)
  • 72% of people taking VANFLYTA with chemotherapy (192 out of 268) and 65% of people taking placebo plus chemotherapy (176 out of 271) achieved composite complete remission of the cancer

VANFLYTA and chemotherapy helped some people stay in remission, known as duration of complete remission, for a median of ~3 years (38.6 months) compared to ~1 year (12.4 months) for people taking placebo and chemotherapy alone.

Next: Possible side effects